An unanswered question in human health is whether antioxidation prevents or promotes
cancer. Antioxidation has historically been viewed as chemopreventive, but emerging …

Highlights•Traditional drug screening model systems are inadequate.•Organoid-on-a-chip
platforms stand to significantly advance drug and toxicology screening.•A wide variety or …

Recent progress in understanding the molecular basis of cellular processes, identification of
promising therapeutic targets and evolution of the regulatory landscape makes this an …

Variability in patient response to anti-cancer drugs is currently addressed by relating genetic
mutations to chemotherapy through precision medicine. However, practical benefits of …

Traditional 2D cell cultures do not accurately recapitulate tumor heterogeneity, and
insufficient human cell lines are available. Patient-derived xenograft (PDX) models more …

With advantageous features such as minimizing the cost, time, and sample size
requirements, organ-on-a-chip (OOC) systems have garnered enormous interest from …

Cell migration is crucial for many biological processes, including normal development,
immune response, and tissue homeostasis and many pathological processes such as …

Precision medicine continues to be the benchmark to which we strive in cancer research.
Seeking out actionable aberrations that can be selectively targeted by drug compounds …

Over the past decade, advances in biomedical and tissue engineering technologies, such as
cell culture techniques, biomaterials, and biofabrication, have driven increasingly …

Cancer harbors variable heterogeneity and plasticity. Thus far, our comprehension is greatly
based on cell lines, organoids, and patient-derived tumor xenografts (PDTXs). Organoids …